Roche Holding AG (RHHBF)
| Market Cap | 280.14B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 23.63 |
| Forward PE | 13.98 |
| Dividend | 10.97 (3.27%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 2 |
| Average Volume | 185 |
| Open | 340.28 |
| Previous Close | 335.90 |
| Day's Range | 340.28 - 340.28 |
| 52-Week Range | 280.85 - 395.28 |
| Beta | 0.18 |
| RSI | 39.79 |
| Earnings Date | Oct 27, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, ...
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the ...
Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases
BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration a...
Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva has the potential to be a transfo...
Positive phase III data for Roche's Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuz...
Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the ...
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Roche purchases shares in tender offer for 89bio, Inc
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered a...
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue
Basel, 29 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark for its Elecsys® Dengue Ag test – a high-throughput, fully automated immunoassay to be used as ...
Genentech's Gazyva Meets Primary Endpoint In Idiopathic Nephrotic Syndrome Phase III Trial
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that its Phase III INShore study evaluating Gazyva (obinutuzumab) in children and young adults aged 2 to 25 years with idiopathic ...
Positive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the P...
Notable healthcare headlines for the week: UnitedHealth, Molina and Roche in focus
Get the latest healthcare stock market highlights, key earnings updates, major buyouts, and global drug pricing news.
Roche Holding AG (RHHBY) Q3 2025 Sales Call Transcript
Roche Holding AG (OTCQX:RHHBY) Q3 2025 Sales Call October 23, 2025 8:00 AM EDTCompany ParticipantsThomas Schinecker - Group Chief Executive OfficerAlan...
Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Ex...
Roche raises guidance on forecast-beating nine-month sales
Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow
Top 3 Health Care Stocks You'll Regret Missing In October
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go ...
FDA Approves Roche's Gazyva for Lupus Nephritis
FDA Approves Roche's Gazyva for Lupus Nephritis
My Top 3 Pharma Stocks
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o...
Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche
Rapt stock surged Monday after the biotech company said its experimental hives treatment topped Roche's Xolair in a 16-week study.
'Why the world is falling to bits?': Roche on his upcoming book
David Roche, president of Quantum Strategy discusses his new book, "Consequences: The Rise of a Fractured World Order" which talks about the global state of democracy and what entities are profiting o...
Roche's Gazyva Gets FDA Approval for Lupus Nephritis
The Food and Drug Administration approved Gazyva for the treatment of adults receiving standard therapy for a form of lupus that targets the kidneys.
Roche: FDA Approves Gazyva/Gazyvaro In Treatment Of Lupus Nephritis
(RTTNews) - Roche (RHHBY.PK) announced the FDA has approved Gazyva/Gazyvaro for the treatment of adult patients with active lupus nephritis who are receiving standard therapy, as well as a shorter 90-...